|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Autoimmune Diseases (Autoimmune Disease)
|1.||Blazar, Bruce R: 95 articles (11/2015 - 01/2002)|
|2.||Antin, Joseph H: 84 articles (11/2015 - 03/2002)|
|3.||Martin, Paul J: 68 articles (11/2015 - 01/2002)|
|4.||Anasetti, Claudio: 65 articles (10/2015 - 01/2002)|
|5.||Ferrara, James L M: 64 articles (04/2015 - 01/2002)|
|6.||Storb, Rainer: 63 articles (11/2015 - 01/2002)|
|7.||Lee, Stephanie J: 62 articles (11/2015 - 07/2002)|
|8.||Holler, Ernst: 54 articles (11/2015 - 09/2002)|
|9.||Reddy, Pavan: 54 articles (05/2015 - 03/2002)|
|10.||Teshima, Takanori: 53 articles (10/2015 - 01/2002)|
|1.||Cyclosporine (Ciclosporin)FDA LinkGeneric
05/01/1985 - "Withdrawal of cyclosporin A, which is highly effective in preventing graft-versus-host disease, can be fatal. "
07/17/1982 - "Oral cyclosporin A is extremely effective at reducing the severity of graft-versus-host disease, but prevention of the disease is limited by toxicity of the drug and variable absorption. "
09/01/2013 - "The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL."
12/01/2009 - "After a minimum of a 2-month course of treatment with more frequent dosing of cyclosporine 0.05% (3 times a day in 7 patients and 4 times a day in 15 patients), overall dry eye symptoms were improved in 15 (68.2%) patients (9 patients with ocular graft-versus-host disease and 6 patients with Sjögren's syndrome). "
11/01/1996 - "Signs and symptoms of ulcerative oral graft-versus-host-disease improved more than 50% in three of four patients with oral graft-versus-host disease treated with the addition of topical cyclosporine. "
|2.||Methotrexate (Mexate)FDA LinkGeneric
08/01/2005 - "Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease."
03/01/2004 - "Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial."
01/01/1976 - "Based upon animal studies, attempts were made to prevent graft-versus-host disease in humans by the use of methotrexate following grafting. "
02/01/2016 - "This approach has the advantage of avoiding methotrexate for graft versus host disease (GVHD) prophylaxis. "
04/01/2014 - "Low-dose methotrexate (LD-MTX) has long been included in prophylaxis regimens for acute graft-versus-host disease (aGVHD). "
|3.||Tacrolimus (Prograf)FDA LinkGeneric
07/01/1997 - "Tacrolimus (FK506) is a macrolide lactone effective in the control of graft-versus-host disease (GVHD). "
09/01/2003 - "Topical tacrolimus--a novel treatment alternative for cutaneous chronic graft-versus-host disease."
03/01/2015 - "Only a few studies in children have evaluated the efficacy of prophylactic regimens using tacrolimus on acute graft-versus-host disease (aGVHD). "
03/01/2007 - "Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease."
02/01/2005 - "Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease."
|4.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/01/2007 - "This study was aimed to investigate a new method of avoiding graft-vs-host disease (GVHD) through selective elimination of alloreactive donor lymphocytes by using total body irradiation (TBI) and cyclophosphamide (Cy). "
08/01/1968 - "In these studies adult mice treated with cyclophosphamide and foreign immunologically competent cells developed a graft versus host disease which outwardly resembled that encountered in other experimental systems. "
04/01/2015 - "Cyclophosphamide's lack of hematopoietic stem cell toxicity and its unique effects on the immune system have prompted several investigators to explore its potential for the prevention of graft-versus-host disease (GVHD). "
09/25/2014 - "Posttransplantation cyclophosphamide (PTCy) is an effective prophylaxis against graft-versus-host disease (GVHD). "
11/01/2012 - "Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice."
|5.||Thalidomide (Thalomid)FDA Link
05/01/1996 - "Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs.-host disease (GVHD). "
11/01/1995 - "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). "
01/01/1995 - "We describe a protocol for monitoring patients treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects."
08/01/1999 - "This interaction is a possible explanation for the diverse types of malformations caused by thalidomide and may also account for its immunosuppressant action which makes it useful in the treatment of graft-versus-host disease."
04/01/2003 - "Studies of thalidomide in chronic graft-versus-host disease showed benefit in children and adults as treatment, but not as prophylaxis. "
11/01/2004 - "Improved cellular immunity after T-cell-depleted haploidentical HPCT will thus require novel strategies to adoptively transfer antigen specific donor T-cells without inducing lethal graft-versus-host disease (GvHD). "
06/01/2000 - "Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model."
12/01/2008 - "In this study, we tested the effect of different T-cell subpopulations on antigen driven effector cell expansion in lymphopenic hosts, making use of an experimental model of graft-versus-host disease (GVHD). "
09/15/2001 - "In the current study we provide an in vitro basis to address the question of whether mismatches for this antigen are a risk factor for acute graft-versus-host disease (GVHD). "
04/01/2015 - "Human leucocyte antigen (HLA) compatibility is the main factor determining the occurrence of graft-vs-host disease (GVHD) in patients. "
|7.||alemtuzumab (Campath)FDA Link
07/01/2012 - "Factors predicting OS (P value by log rank <0·05) were: comorbidity index <3, FISH rank (Dohner) and 17p deletion, alemtuzumab pre-HSCT, achievement of CR post-HSCT, donor chimerism >90%, clearance of FISH abnormality post-HSCT and absence of high-grade (3-4) graft-versus-host disease. "
01/01/2014 - "The incidence of de novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for GVHD prophylaxis. "
05/01/2013 - "Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease."
05/01/2009 - "Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study."
10/01/2015 - "The incidence of severe acute graft-versus-host disease tended to be higher after the lower alemtuzumab dose (17% versus 4%; P = .15). "
|8.||mycophenolate mofetil (Cellcept)FDA LinkGeneric
09/01/2015 - "Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?"
01/01/2006 - "We enrolled 11 patients with refractory graft-versus-host disease (GVHD) in a prospective trial evaluating the efficacy of mycophenolate mofetil (MMF). "
05/21/2009 - "We conducted a double-blind, randomized multicenter trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment of chronic graft-versus-host disease (GVHD). "
04/01/2005 - "Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease."
11/01/2014 - "Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis."
|9.||Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
09/01/2008 - "Inclusion of antithymocyte globulin led to a better day 100 overall response rate (93% vs. 78%, p=0.03) and complete response rate (59% vs. 39%, p=0.04), to a lower incidence of both acute grade III/IV graft-versus-host-disease (11% vs. 22%, p=0.10) and chronic graft-versus-host disease (23% vs. 65%, p<0.001) and to a trend to improved event-free survival at 3 years (39% vs. 27%, p=0.5). "
09/01/2002 - "The efficacy of antithymocyte globulin (ATG) in the treatment of graft-versus-host disease (GvHD) is controversial. "
01/01/2015 - "Recent studies showing the addition of antithymocyte globulin (ATG) to the conditioning regimen improves engraftment and reduces the risk of graft-versus-host disease (GVHD).There are currently two ATG preparations in the USA, equine (or horse) and rabbit ATG. "
08/01/2007 - "The objective of study was to investigate the effect of low-dose antithymocyte globulin (ATG) on steroid-resistant severe acute graft versus host disease (aGVHD). "
11/01/2005 - "Results from few randomized trials show that antithymocyte globulin reduces acute and chronic graft-versus-host disease, and this is in keeping with results from retrospective analysis on large number of patients. "
|10.||rituximab (Mabthera)FDA Link
08/01/2003 - "Nine patients not achieving a complete remission (CR) post SCT converted to CR with rituximab and with the onset of graft-versus-host disease (GVHD) in three. "
11/01/2010 - "Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. "
03/01/2007 - "Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease."
01/01/2006 - "Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease."
09/01/2009 - "Increased insight into the role of B lymphocytes in the pathophysiology of graft-versus-host disease has led to a number of studies assessing the efficacy of the anti-CD20 monoclonal antibody (mAb) rituximab in treating steroid-refractory chronic graft-versus-host disease (cGVHD). "
11/01/2015 - "Initial attempts at HSCT were discouraging and fraught with complications, but with increased knowledge and sophistication of HLA typing and donor matching, development of improved transplant conditioning regimens, and advances in prophylaxis and treatment of graft-versus-host disease, there has been a marked improvement in outcomes. "
01/01/2013 - "By multivariate Cox regression analysis, disease status of complete response (CR) or partial response (PR) at transplant and the presence of chronic graft-versus-host disease were significantly associated with improved OS. "
06/01/2005 - "Limited chronic graft-versus-host-disease (GVHD) was associated with an improved DFS of 53% (CI 38-69%) compared to no chronic GVHD of 22% (CI 10-36%; P=0.0008), indicating a clinically important graft-versus-leukaemia effect."
03/01/2003 - "Five gradually incremental DLI achieved complete donor chimerism, which was associated not only with grade II graft-versus-host disease (GVHD), but also with complete clinical and biological remission for 2 years post-transplant. "
07/01/2002 - "The close relation (P = 0.0075) between the first occurrence of graft-vs.-host disease and the complete clearance of bcr/abl positive blood cells argues in favour of an effective graft-vs.-leukaemia reaction."
|2.||Transplantation (Transplant Recipients)
09/30/2010 - "Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. "
12/01/2010 - "Experimental models are providing very important data on the in-vitro and in-vivo behavior of Tregs in transplantation, while recent clinical trials of Treg cellular therapy in graft-versus-host disease are offering a valuable insight into the efficacy of Treg adoptive cellular therapy. "
05/01/2008 - "Four years after the transplantation, she remains in complete remission without graft-versus-host disease or any other symptoms. "
02/01/2004 - "Twenty-three months after transplantation, the child is in continuous complete remission and has full donor chimerism and no signs of chronic graft-versus-host disease."
12/01/2003 - "The patient developed no graft-versus-host disease (GVHD) and remains in complete remission 16 months after the transplantation. "
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/01/2014 - "Regulatory T cells (Treg)s attenuate excessive immune responses, making their expansion beneficial in immune-mediated diseases including allogeneic bone marrow transplantation (BMT)-associated graft-versus-host disease (GVHD). "
11/03/2009 - "We have found that intra-bone marrow-bone marrow transplantation (IBM-BMT) is superior to conventional intravenous BMT, since IBM-BMT enables rapid recovery of donor hematopoiesis and reduces the extent of graft-versus-host disease (GVHD). "
06/15/2011 - "Graft versus host disease (GVHD) is the major complication of allogeneic bone marrow transplantation (BMT) and limits the therapeutic efficacy of this modality. "
05/25/2004 - "Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). "
05/01/2004 - "A reduced incidence of graft versus host disease (GvHD) has been documented among Japanese allogeneic bone marrow transplantation (BMT) patients, as the Japanese are genetically more homogeneous than western populations. "
|4.||Hematopoietic Stem Cell Transplantation
02/01/2014 - "Early reports demonstrated the safety of adherent mesenchymal stromal cell (MSC) infusions in the hematopoietic stem cell transplantation (HCT) setting, as well as clinical efficacy for treatment of steroid refractory acute graft-versus-host disease (GVHD); however, two large, Phase III randomized, placebo-controlled trials of MSC for initial therapy or steroid refractory GVHD failed to meet their primary endpoints of durable complete response. "
04/16/2009 - "Chronic graft-versus-host disease (cGVHD) causes significant morbidity and mortality in patients otherwise cured of malignancy after hematopoietic stem cell transplantation (HSCT). "
08/01/2009 - "Mesenchymal stem cells emerged as a promising treatment modality for steroid-refractory graft-versus-host disease, which represents a major complication of allogeneic hematopoietic stem cell transplantation. "
02/15/2006 - "We hypothesized that absence of the beta7 subunit would result in a reduction of intestinal graft-versus-host disease (GVHD) and an improvement in overall GVHD morbidity and mortality in recipients of hematopoietic stem cell transplantation (HSCT). "
03/01/2013 - "Colonoscopic evaluation of mucosal tissues after allogeneic hematopoietic stem cell transplantation (HSCT) is very useful in evaluating pathogenesis and diagnosis of intestinal graft-versus-host disease (GVHD). "
|5.||Stem Cell Transplantation
01/01/2010 - "Improved outcome after allogeneic stem cell transplantation (allo-SCT), despite a high incidence of graft-versus-host disease, has been reported. "
04/01/2015 - "Currently, detecting biochemical differences before and after allogeneic stem cell transplantation (SCT) for improved prediction of acute graft-versus-host disease (aGVHD) is a major clinical challenge. "
09/01/2007 - "Acute and chronic graft-versus-host disease (GVHD) remain the major complications limiting the efficacy of allogeneic hemopoietic stem cell transplantation. "
03/01/2005 - "UVA1 as an adjunct to systemic immunosuppressive treatment was found to be safe, and effective in 10 patients with chronic cutaneous (seven lichenoid and three sclerodermoid) graft-versus-host disease (GVHD) after stem cell transplantation. "
06/01/2014 - "In haematopoietic stem cell transplantation, iCasp9-modified donor T cells can be rapidly eliminated in the event of graft-versus-host disease. "